Belančić A - Search Results

1

A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy.

Belančić A, Faour AK, Gkrinia EMM, Vitezić D. Belančić A, et al. Br J Clin Pharmacol. 2024 Oct 8. doi: 10.1111/bcp.16267. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 39378908 Review.

2

Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data.

Belančić A, Strbad T, Kučan Štiglić M, Vitezić D. Belančić A, et al. J Clin Med. 2023 Apr 13;12(8):2839. doi: 10.3390/jcm12082839. J Clin Med. 2023. PMID: 37109175 Free PMC article.

3

Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety.

Belančić A, Strbad T, Kučan Štiglić M, Vitezić D. Belančić A, et al. J Pers Med. 2024 Feb 24;14(3):244. doi: 10.3390/jpm14030244. J Pers Med. 2024. PMID: 38540986 Free PMC article.

4

Afatinib-induced toxic epidermal necrolysis: A case report with a literature review.

Belančić A, Hlača N, Peternel S, Golčić M, Prpić-Massari L, Vlahović-Palčevski V. Belančić A, et al. Br J Clin Pharmacol. 2024 Aug;90(8):2030-2033. doi: 10.1111/bcp.16114. Epub 2024 May 27. Br J Clin Pharmacol. 2024. PMID: 38803188 Review.

5

Past, present and future of drug safety: Editorial.

Rieder M, Belančić A. Rieder M, et al. Among authors: belancic a. Br J Clin Pharmacol. 2024 Aug;90(8):1760-1762. doi: 10.1111/bcp.16140. Epub 2024 Jun 16. Br J Clin Pharmacol. 2024. PMID: 38880969 No abstract available.

6

Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.

Belančić A, Pavešić Radonja A, Ganoci L, Vitezić D, Božina N. Belančić A, et al. Croat Med J. 2024 Aug 31;65(4):383-395. doi: 10.3325/cmj.2024.65.383. Croat Med J. 2024. PMID: 39219201 Free PMC article. Review.

7

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury.

Harej Hrkać A, Pilipović K, Belančić A, Juretić L, Vitezić D, Mršić-Pelčić J. Harej Hrkać A, et al. Among authors: belancic a. Pharmaceuticals (Basel). 2024 Oct 1;17(10):1313. doi: 10.3390/ph17101313. Pharmaceuticals (Basel). 2024. PMID: 39458954 Free PMC article. Review.

8

Letter to the editor: Personalized antihypertensive treatment-The role of body fat indices beyond body mass index.

Antza C, Belančić A, Jelaković A. Antza C, et al. Among authors: belancic a. Br J Clin Pharmacol. 2024 Oct 28. doi: 10.1111/bcp.16332. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 39467811 No abstract available.

9

Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?

Belančić A, Faour AK, Gkrinia EMM, Vitezić D. Belančić A, et al. Croat Med J. 2024 Oct 31;65(5):454-456. doi: 10.3325/cmj.2024.65.454. Croat Med J. 2024. PMID: 39492456 Free PMC article. No abstract available.

10

European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology.

Belančić A, Sans-Pola C, Jouanjus E, Alcubilla P, Arellano AL, Žunić M, Nogueiras-Álvarez R, Roncato R, Sáez-Peñataro J; EACPT Young Clinical Pharmacologists Working Group. Belančić A, et al. Eur J Clin Pharmacol. 2022 Apr;78(4):691-694. doi: 10.1007/s00228-022-03277-3. Epub 2022 Jan 17. Eur J Clin Pharmacol. 2022. PMID: 35037981 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters